Abbott Laboratories (ABT)

FY2025 revenue was approximately $42B, growing ~8% organically excluding COVID testing. This compares favorably to peers like Medtronic (~5%) and Becton Dickinson (~5%), though trails faster-growing pure-play medtech names like Intuitive Surgical. The growth is broad-based across three of four segments.

FreeStyle Libre has captured dominant global CGM share, particularly in Europe and increasingly in the US, surpassing 6 million users. Abbott is successfully expanding CGM into Type 2 diabetes (a 10x larger patient population than Type 1) and the over-the-counter wellness market with Lingo. Medical devices are gaining share in structural heart with the TriClip and Amulet platforms.

CGM pricing is under modest pressure as Libre competes with Dexcom on a value proposition — Abbott wins on price while Dexcom wins on accuracy perception. Nutritional products (Ensure, Pedialyte) have moderate pricing power in a branded consumer health market. Diagnostics instruments are razor-and-blade models with limited consumable pricing flexibility.

Libre 3 is a strong next-gen sensor with improved accuracy and the thinnest form factor on the market. The Lingo wellness CGM is a novel expansion into direct-to-consumer health monitoring. However, Abbott's pipeline in medical devices is solid but not revolutionary — TriClip and Amulet are fast-followers, not first-movers.

Hospital systems and lab networks that standardize on Abbott diagnostics platforms face significant switching costs in training, workflow integration, and validation. CGM users develop strong brand loyalty through app ecosystem and familiarity. Nutritional brand loyalty (Similac, Ensure) is high among healthcare professionals who recommend these products.

Limited direct network effects. The LibreView data platform creates some provider ecosystem stickiness as more clinicians use it for remote patient monitoring. The diagnostics installed base creates a weak but real network effect as hospitals prefer platforms compatible with their existing Abbott infrastructure.

Abbott holds extensive FDA clearances and CE marks across its product lines, creating significant regulatory barriers to entry. The CGM space requires rigorous clinical trials for accuracy claims. Abbott's patent estate around sensor chemistry and factory calibration technology is substantial and well-defended.

Abbott generates $8B+ in free cash flow annually on moderate capex requirements. The diversified business model smooths earnings volatility — when diagnostics dips, devices or nutritionals pick up. This FCF stability supports a consistent buyback and dividend program that has compounded shareholder value for decades.

FY2026 EPS estimates have edged up ~4% over the past six months, reflecting consistent Libre beat-and-raise quarters. The Street models mid-to-high-single-digit earnings growth, which is achievable but not exciting. Upside revisions have been steady rather than dramatic.

The Libre growth story dominates the narrative and is well understood by the market. The OTC wellness CGM category expansion (Lingo) is generating buzz. However, the infant formula safety narrative from 2022 lingers in public perception, and any new product safety issues could disproportionately impact sentiment.

CEO Robert Ford has executed well on the post-COVID transition and the Libre growth strategy. Capital allocation is balanced between organic investment, bolt-on M&A, and shareholder returns. Abbott lacks the transformative deal-making appetite of peers like Stryker, which may limit upside optionality but also reduces integration risk.